Skip to content

A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)

A Secondary Study Evaluating Performance and Safety of Aqueduct's Smart External Drain (SED2)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03471702
Enrollment
12
Registered
2018-03-21
Start date
2018-02-28
Completion date
2018-11-01
Last updated
2019-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydrocephalus, Hydrocephalus in Children, Subarachnoid Hemorrhage, Tumor, Brain

Brief summary

Aqueduct's Smart External Drain (SED) will be compared to the current gold standard for temporary CSF management in a hospital setting. * Evaluate the number of subjects requiring to be switched to a standard of care EVD * Evaluate subject transport while on the SED * Evaluate SED system control from initiation of SED through discharge of external drain system

Detailed description

This clinical trial will evaluate Aqueduct's Smart External Drain (SED) upon implementation of ventriculostomy or lumbar drain placement for temporary CSF external management in a hospital setting. Subjects will remain on study from the time of SED application through discharge of the external drain or switch to standard of care extraventricular drain.

Interventions

Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.

Sponsors

Aqueduct Critical Care
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Subject scheduled to have an external drain (includes extra-ventricular and lumbar drains) placed as part of routine management. 2. Age 0-80. 3. Able to obtain consent or legally authorized representative (LAR) consents for subject to be treated on study.

Exclusion criteria

1. Anticoagulant therapy (does not include DVT or PE prophylaxis). 2. Known bleeding diathesis. 3. Scalp infection. 4. In the opinion of the Investigator the subject is not a good study candidate.

Design outcomes

Primary

MeasureTime frameDescription
The number of subjects which require switching to a standard of care external drain.The study review and data collection period will begin at the time SED is connected to the ventriculostomy catheter until discharge of ventriculostomy catheter; when subject no longer requires an external drain, assessed up to 90 days.Evaluating the number of subjects which require switching to a standard of care external drain versus the number of subjects which remain on the SED until study completion or discharge of the external drain.

Secondary

MeasureTime frameDescription
Subject transport while on the SED system.Subject transport review and data collection will begin when the patient is moved from their primary hospital bed location until they reach a new secondary location or are returned to the primary location. Assessed up to 90 days.Evaluating subject transport while on the SED system, specifically, the number of minutes a subject will require clamping of the drain while being transported.
Evaluating SED system control throughout duration of study.The study review and data collection period will begin at the time SED is connected to the ventriculostomy catheter until discharge of ventriculostomy catheter; when subject no longer requires an external drain, assessed up to 90 days.SED system control will be evaluated from initiation of ICP management through discharge of the subject's external drain.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026